At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 67 enrolled
Drug / intervention
GDC-0449 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib, Open-Label, Dose-Scheduling Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
In Brief
A Phase 1 clinical trial evaluating GDC-0449 for Solid Cancers. Completed, enrolled 67 participants.
Detailed Summary
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Cancers
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionOct 2010
TodayJul 2026
First PostedAug 31, 2009
Enrollment StartSep 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.8 years ago
Interventions
GDC-0449drug
Daily oral repeating dose
GDC-0449drug
Three times weekly oral repeating dose
GDC-0449drug
Once weekly oral repeating dose